FDA’s ‘Accelerated Approvals’ Are Critical But Raise Thorny Issues

Ítems similars

• Flexibility and innovation in the FDA’s novel regulatory approval strategies for hematologic drugs
  per: Farrell, Ann T., et al.
  Publicat: (2017)
• FDA’s commitment to transparency
  per: Guharoy, Roy, et al.
  Publicat: (2021)
• Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
  per: Kesselheim, Aaron S., et al.
  Publicat: (2016)
• The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
  per: Marks, Peter
  Publicat: (2019)
• Critics Assail FDA Medical Device Approval Process: Slow Review Time and Safety Are at Issue
  per: Barlas, Stephen
  Publicat: (2011)